Even in the worst crises, there is a need for medicine, and it has Novo Nordisk benefited in the first six months.
In the period have a larger sales have been to increase the surplus for the Danish medicinalgigant. It shows the half yearly financial information from the company.
Overall, Novo Nordisk is in the first six months of earned 22.5 billion dollars. This is an increase of 12 percent compared to the same period the year before.
Behind the increased profits is a turnover, which compared to the first half of last year has increased by eight percent to 63,9 billion dollars.
Novo Nordisk explains itself, that the sales growth in the first half of the year have been positively affected by customers ' stock-building, which has been related to coronaudbruddet.
It is, however, mainly in the first quarter that customers have really bought in to their store. In the second quarter, the customers have again reduced the stocks.
Common to the first and second quarter is that fewer patients according to Novo Nordisk has started the new treatment. It has kept the sales growth returned for the first half of the year.
Regardless of is management satisfied with the economic development that has been in the first six months.
Despite covid-19 is satisfied with the results in the first half of 2020, and with the progress we have made in our strategic ambitions, " says Lars Fruergaard Jørgensen, executive director at Novo Nordisk, in a comment.
The largest business area in Novo Nordisk is the development of agents for the treatment of diabetes. With more than 90 years of experience, the company is today one of the largest players in the field of diabetes treatment.
According to Søren Løntoft Hansen, analyst in Sydbank, facing Novo Nordisk with the best products on the market for diabetes treatment. It is the reason that the company continues to sell as much as it does.
- The product portfolio, such as Novo Nordisk has, in my assessment, also contribute to growth in the coming years, says Søren Løntoft Hansen.
It is particularly in the UNITED states, Novo Nordisk has a large sale of its products. Here, in the first half of the year alone has been sold for 27.8 billion dollars.
It is almost half of the company's total revenue of 63.9 billion.